CRSP

CRISPR Therapeutics AG is a gene editing company focused on developing transformative medicines using CRISPR/Cas9 technology. Headquartered in Zug, Switzerland with U.S. operations in Cambridge, Massachusetts, the company is advancing a diverse portfolio of programs in areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. CRISPR Therapeutics gained FDA approval for Casgevy (exagamglogene autotemcel) in 2023, the first CRISPR-based gene therapy approved in the United States. The company maintains strategic partnerships with Vertex Pharmaceuticals and other leading healthcare organizations.